Opportunistic biotech trading bitch with a focus on nucleic acid-based and -targeted biotech. Fiercely independent. https://t.co/dfLqOuH7Uh
Cite asCryptoQuant has tracked the directional calls on ARWR by @RNAiAnalyst on X since Aug 2025: not yet scored on ARWR (as of Nov 11, 2026).
Other assets covered (14)
Relative view by default: fewer than 30 ARWR calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @RNAiAnalyst to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
$PEPG splicing correction accompanied by functional improvement and no cumulative tox. Dare I say home-run data? Come on $ARWR: you can do better with subQ muscle/CNS delivery of MOA like $pepg's. That would be the killer app for DM1.
View original →$ARWR $IONS both companies had told Street to lower its expectations and had been punished for it. But even I did never expect such a horrendous $9M print. Reversion to the mean trade here?
View original →$IONS shocker: just $9M in Q3 sales ofApoc3 trig-lowering ASO. Good/bad for $ARWR? https://t.co/g2yekCVqh1
View original →A changing of the guards in #RNAi in 2027? Stale chip vendor $ARWR to surpass $ALNY in market cap?
View original →Great 60% htt knockdown at single doses already. Uses intrathecal delivery, so striatal knockdown for this exon1-targeter could be modest and complementary with $QURE's striatal delivery. $ALNY $ARWR https://t.co/zrKtav3zPL
View original →
